The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
How Will The Market Value Of The Huntington’s Disease Treatment Market Increase Between 2026 And 2030?
The Huntington’s disease treatment market has experienced rapid expansion in recent years. This market is projected to expand from $0.82 billion in 2025 to $0.92 billion in 2026, achieving a compound annual growth rate (CAGR) of 12.6%. Historically, this growth can be attributed to several factors, including the scarcity of treatment alternatives for neurodegenerative conditions, a rise in the diagnosis of genetic neurological illnesses, an initial focus on managing symptoms, the broadening of neurology specialty healthcare services, and an increase in neurological treatments provided in hospitals.
The huntington’s disease treatment market is projected for significant expansion over the coming years. It is anticipated to reach $1.48 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.6%. This expansion during the forecast period is driven by progress in gene therapy technologies, increased funding for rare disease research, more orphan drug designations, the growing embrace of precision medicine, and a broader array of disease-modifying therapies in development. Key developments expected during this period include an intensified focus on disease-modifying treatments, wider use of gene and RNA-based therapies, broader application of combination treatment strategies, a greater emphasis on developing symptom-specific drugs, and heightened clinical trial activity for uncommon neurological conditions.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24245&type=smp
What Influential Factors Are Boosting The Huntington’s Disease Treatment Market Demand?
The Huntington’s disease treatment market is anticipated to expand due to the rising adoption of gene therapies. These therapies involve altering or substituting defective genes to prevent or treat illnesses at their fundamental genetic origin. The progression of precision medicine is fueling the expansion of gene therapies, allowing them to precisely target genetic root causes and deliver superior results compared to conventional approaches. In the context of Huntington’s disease, gene therapies work by deactivating the faulty HTT gene, which is responsible for producing detrimental proteins, thereby averting damage to nerve cells. This method aids in decelerating the disease’s advancement, preserving brain capabilities, and presents a prospect for sustained management. An illustration of this trend is seen in data from July 2023, released by the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, which indicated that while there were 247 gene therapies in phase II at the close of Q1 2023, this figure increased by 5% to 260 by the end of Q2. Consequently, the expanding availability of gene therapies is stimulating the expansion of the Huntington’s disease treatment market.
How Are Different Segment Groups Identified Within The Huntington’s Disease Treatment Market?
The huntington’s disease treatment market covered in this report is segmented –
1) By Treatment: Symptomatic Treatment, Disease-Modifying Therapies
2) By Administration Type: Oral, Intravenous, Subcutaneous, Topical
3) By Therapeutic: Genetic Disorders, Neurological Disorders, Psychiatric Disorders
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
5) By End-User: Hospitals, Clinics, Homecare Settings, Research Centers
Subsegments:
1) By Symptomatic Treatment: Antidepressants, Antipsychotics, Mood Stabilizers, Chorea Medications, Cognitive Enhancers
2) By Disease-Modifying Therapies: Gene Therapy, Neuroprotective Agents, RNA-Based Therapies, Stem Cell Therapy, Protein-Targeting Therapies
Which Trends Are Supporting The Evolution Of The Huntington’s Disease Treatment Market?
Leading enterprises in the Huntington’s disease treatment market are concentrating on the development of advanced therapies, such as selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules, with the aim of potentially enhancing patients’ quality of life and decelerating disease progression. Selective VMAT2 inhibitor capsules are medications designed to block the vesicular monoamine transporter 2, a protein essential for packaging neurotransmitters prior to their release in the brain. These drugs contribute to reducing neurotransmitter release, thereby assisting in the management of involuntary movements and related symptoms. For example, in August 2023, Neurocrine Biosciences, Inc., a US-based biotech company, secured approval from the U.S. Food and Drug Administration (FDA) for Ingrezza (valbenazine) capsules for addressing chorea associated with Huntington’s disease (HD) in adults. These capsules represent a once-daily oral VMAT2 inhibitor, which functions by mitigating excessive dopamine signaling in the brain to aid in controlling involuntary movements. The medication is offered in multiple capsule strengths and can be taken either with or without food, presenting a practical dosing choice for patients.
Who Are The Firms Contributing To The Huntington’s Disease Treatment Market Ecosystem?
Major companies operating in the huntington’s disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Neurocrine Biosciences Inc., Wave Life Sciences Ltd., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., uniQure N.V., Prilenia Therapeutics B.V., Sage Therapeutics Inc., Annexon Inc., Alnylam Pharmaceuticals Inc., Sun Pharmaceutical Industries Inc., Dr. Reddy’s Laboratories Ltd., Lupin Limited, Hikma Pharmaceuticals plc, Astellas Pharma Inc., Otsuka Pharmaceutical Co. Ltd., AbbVie Inc.
Access The Complete Huntington’s Disease Treatment Market Report:
https://www.thebusinessresearchcompany.com/report/huntingtons-disease-treatment-global-market-report
Which Region Leads The Huntington’s Disease Treatment Market By Size?
North America was the largest region in the Huntington’s disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the huntington’s disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Huntington’s Disease Treatment Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=24245&type=smp
Browse Through More Reports Similar to the Global Huntington’s Disease Treatment Market 2026, By The Business Research Company
Brain Tumor Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report
Brain And Neuroimaging Devices Market Report 2026
Brain Tumor Drugs Market 2026
https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model